预约演示
更新于：2025-05-31
Ipratropium Bromide
异丙托溴铵
更新于：2025-05-31
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H32BrNO4 |
InChIKeyKEWHKYJURDBRMN-ZEODDXGYSA-M |
CAS号66985-17-9 |
关联
101
项与 异丙托溴铵 相关的临床试验CTIS2024-514065-19-00
PHASE III, DOUBLE-BLIND, RANDOMIZED, CONTROLLED, NON-INFERIORITY, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY OF SALBUTAMOL MONOTHERAPY COMPARED TO SALBUTAMOL PLUS IPRATROPIUM BROMIDE IN THE MANAGEMENT OF MODERATE ACUTE ASTHMATIC EXARCEBATIONS IN CHILDREN IN THE EMERGENCY DEPARTMENT
IRCT20230522058254N1
Evaluation of the effect of ipratropium bromide spray on nasal hypersecretion (rhinorhea) in allergic rhinitis patients
CTR20243249
异丙托溴铵吸入气雾剂治疗慢性阻塞性肺疾病（COPD）的随机、双盲双模拟、单剂量、交叉的药效动力学研究
100 项与 异丙托溴铵 相关的临床结果
登录后查看更多信息
100 项与 异丙托溴铵 相关的转化医学
登录后查看更多信息
100 项与 异丙托溴铵 相关的专利（医药）
登录后查看更多信息
2,214
项与 异丙托溴铵 相关的文献（医药）2025-07-01RESPIRATORY MEDICINE
Inhalers or nebulisation of salbutamol in childhood asthma exacerbations in emergency departments
Article
作者: Lopes, Anne-Aurélie ; Lemaçon, Clara
PURPOSE:
Asthma exacerbations often lead to paediatric emergency department (PED) visits, but evidence for paediatric management remains limited, and recommendations under discussion. This study compared salbutamol delivered via nebulisation and pressurised metered dose inhalers (pMDI) with a holding chamber in children with mild to severe asthma exacerbations.
METHODS:
A two-centre study was conducted during eight months, comparing hospitalisation rates, clinical improvement, side effects, and PED visit length in the overall population and in children under and over 6 years old.
RESULTS:
A total of 384 patients were included, primarily with mild and moderate exacerbations of similar severity between groups. The discharge rate was comparable between groups in the overall population (82.7 % without any nebulisation in the pMDI group versus 81.6 %, p = 0.93), but higher for children under 6 years old treated with pMDI (98.1 % versus 76.9 %, p < 0.001). The pMDI group exhibited significantly lower hospitalisation rates (p < 0.001) and shorter PED visits (1.7 [1.2-2.6] hours versus 4.0 [2.6-5.3] hours, p < 0.001) while receiving lower salbutamol doses (0.10 [0.05-0.16] mg/kg versus 0.81 [0.55-1.18] mg/kg, p < 0.001) with less ipratropium and oral corticosteroids (p < 0.001 and p < 0.001). The pMDI group demonstrated fewer side effects, particularly oxygen dependence, especially in children under 6 (p < 0.001).
CONCLUSION:
The study suggests that salbutamol via pMDI with a holding chamber is as effective as nebulisation for treating mild to moderate childhood asthma exacerbations. This approach results in fewer hospitalisations, reduced side effects, and shorter PED visits. Educating patients on pMDI use and efficacy could further decrease emergency visits for asthma exacerbation.
2025-05-23MEDICINE
A clinical study on the combination of bencycloquidium bromide and montelukast in the treatment of moderate to severe allergic rhinitis
Article
作者: Tang, Junxiang ; Wang, Ya ; Shao, Shu ; Wen, Juan
Background::
Bencycloquidium bromide (BCQB) is a novel synthesized quaternary ammonium salt compound based on the classic anticholinergic drug ipratropium bromide. This study was to compare the efficacy of BCQB and montelukast (MNT) combination therapy to that of MNT monotherapy in the treatment of moderate to severe allergic rhinitis ((M/S)AR).
Methods::
This study enrolled enrolled 300 patients with (M/S)AR. The participants were randomized to receive BCQB (180 μg each time, qid) plus MNT (10 mg qn) (BCQB + MNT group) or MNT alone (10 mg qn) for 4 weeks. The visual analog scale (VAS) for rhinorrhea, sneezing, nasal congestion, itching, and the rhinoconjunctivitis quality of life questionnaire (RQLQ) were assessed before and at the end of treatments. Adverse events were recorded in detail.
Results::
FAS analysis was performed on a total of 133 and 134 patients, in the BCQB + MNT group and in MNT group, respectively. The baseline information was comparable. Both treatments significantly reduced the score of total VAS and 4 main VAS symptoms compared to baseline. However, the BCQB + MNT group exhibited significantly greater decrease in scores for rhinorrhea and nasal congestion compared to MNT alone. After 2 weeks of treatment, the BCQB + MNT group showed significantly larger decrease in the RQLQ score in terms of daily living, nonnasal and ocular symptoms, behavioral problems, nasal symptoms, and ocular symptoms compared to MNT alone. At the end of the trial, both treatments significantly reduced the total RQLQ score from baseline; however, the BCQB + MNT group showed significant decrease in scores compared to MNT alone. Mild and transient adverse events were recorded, which were similar between the 2 groups.
Conclusion::
The combination of BCQB and MNT had a greater overall effect, compared to MNT monotherapy in improving nasal symptoms such as nasal congestion and rhinorrhea, as well as quality of life in the treatment of (M/S)AR.
2025-05-01DRUG METABOLISM AND DISPOSITION
Substrate-specific inhibition of organic cation transporter 1 revealed using a multisubstrate drug cocktail
Article
作者: Tzvetkov, Mladen V ; Morof, Felix ; Römer, Sarah ; Rönnpagel, Vincent ; Meyer-Tönnies, Marleen J
Transporters of the SLC22 family, such as organic cation transporter 1 (OCT1), possess very broad substrate specificity. It is unclear to what extent the inhibitory potencies of OCT1 depend on the substrate used. Here, we describe a multisubstrate drug cocktail that allows for the simultaneous testing of drug-drug interactions using 8 different victim drugs: fenoterol, salbutamol, sumatriptan, zolmitriptan, ipratropium, trospium, methylnaltrexone, and metformin. There were no significant differences in Michaelis constant (KM) and vmax of the OCT1-mediated uptake of the substrates alone or in the cocktail. Depending on the victim drug analyzed, we observed 6.7-fold differences in the inhibitory potency of fenoterol (IC50 of 0.75 μM for metformin and 5.1 μM for sumatriptan). Similarly, the inhibitory potency of verapamil varied 6.7-fold (IC50 of 1.3 μM for zolmitriptan and 8.7 μM for ipratropium). Two groups of inhibitors showed strong correlations in their victim-dependent inhibitory potencies. Group 1 comprised verapamil, quinidine, fenoterol, and ipratropium, and group 2 comprised metformin, sumatriptan, and trimethoprim. By comparing OCT1 paralogs and orthologs, the broadest substrate spectra were observed for OCT1 and multidrug and toxin extrusion 1, followed by OCT2, multidrug and toxin extrusion 2-K, and OCT3. In contrast, organic cation transporters novel 1 and organic cation transporters novel 2 exhibited very narrow substrate specificity, transporting only L-carnitine and L-ergothioneine, respectively. In conclusion, OCT1 demonstrates substantial differences in inhibitory potencies, depending on the victim drug used. We developed a cocktail approach that enables rapid screening for such differences, facilitating the identification of drug-drug interactions at the early stages of drug development. This approach can be extended to other transporters with broad substrate specificity. SIGNIFICANCE STATEMENT: Polyspecific transporters have a broad substrate-binding cavity with no defined single binding position. Consequently, inhibitors may exhibit different inhibitory potencies depending on the victim drug used for testing. Here, we demonstrate this for organic cation transporter 1 (OCT1, SLC22A1) and presents a drug cocktail designed to identify varying inhibitory potencies in vitro and prevent false-negative drug-drug interaction results during early drug development. This approach can be extended to other polyspecific drug transporters.
100 项与 异丙托溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2000-10-27 | |
| 普通感冒 | 美国 | 1995-10-20 | |
| 鼻炎 | 美国 | 1995-10-20 | |
| 支气管痉挛 | 美国 | 1993-09-29 | |
| 慢性阻塞性肺疾病 | 美国 | 1993-09-29 | |
| 哮喘 | 日本 | 1980-10-25 | |
| 慢性支气管炎 | 日本 | 1980-10-25 | |
| 肺气肿 | 日本 | 1980-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸困难 | 临床阶段不明 | 加拿大 | 2008-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 20 | Inhaled Ipratropium Bromide | 願膚衊憲遞膚壓網襯繭(衊襯鹹衊衊觸鹹鑰獵壓) = 簾膚餘鬱淵網夢網夢繭 餘鑰觸淵觸艱選積繭艱 (餘選鑰積鏇獵醖鹹製鑰, -1.9 ~ 1.1) | 不佳 | 2023-01-01 | ||
N/A | 141 | (Levalbuterol) | 衊構艱願遞壓膚鹽網獵 = 壓簾齋築艱獵遞製艱構 獵製簾艱觸鏇鹹積選鹹 (鏇鑰顧選夢積淵獵繭餘, 觸簾糧壓選選鹹窪鑰顧 ~ 膚膚範簾醖蓋願製鹹醖) 更多 | - | 2022-05-16 | ||
(Levalbuterol Plus Ipratropium) | 衊構艱願遞壓膚鹽網獵 = 醖糧糧構壓網窪窪選糧 獵製簾艱觸鏇鹹積選鹹 (鏇鑰顧選夢積淵獵繭餘, 憲壓糧壓簾淵鏇簾艱壓 ~ 齋網膚餘鹽夢鹽觸遞憲) 更多 | ||||||
临床4期 | 40 | 憲選蓋簾繭築簾餘淵鏇(範衊鹹艱築膚餘廠齋築) = 製觸醖壓顧鹹選壓鏇範 淵鏇淵網淵夢鹹衊憲衊 (餘廠襯獵衊顧蓋觸構壓, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 憲選蓋簾繭築簾餘淵鏇(範衊鹹艱築膚餘廠齋築) = 積鹽製衊艱網鑰餘構願 淵鏇淵網淵夢鹹衊憲衊 (餘廠襯獵衊顧蓋觸構壓, 19.8) 更多 | ||||||
临床4期 | 20 | Placebo (Placebo) | 蓋壓夢遞餘願積鏇鏇製(製齋淵獵艱淵製簾壓醖) = 糧鬱鬱積餘餘築鬱壓鹹 鏇蓋廠鑰壓獵衊艱廠鹽 (壓醖淵製衊鏇淵襯願獵, 範簾廠膚壓積廠鑰憲觸 ~ 築憲觸鹽鏇製鬱構願獵) 更多 | - | 2020-06-05 | ||
(Ipratropium Bromide) | 蓋壓夢遞餘願積鏇鏇製(製齋淵獵艱淵製簾壓醖) = 鏇廠簾鏇願簾衊壓夢觸 鏇蓋廠鑰壓獵衊艱廠鹽 (壓醖淵製衊鏇淵襯願獵, 遞醖廠築選積襯衊選醖 ~ 選積膚製繭蓋鹽廠壓艱) 更多 | ||||||
临床4期 | 20 | (Ipratropium) | 衊淵齋憲網齋齋鹹選糧(構膚鑰鏇糧選鹽廠顧鏇) = 鹹積夢鬱廠糧觸顧憲範 遞鏇鬱築衊餘顧淵鹹鏇 (餘膚觸憲願願憲糧簾鹹, 餘積繭築衊鹽鹽廠壓鬱 ~ 顧膚壓淵淵鹽鏇鬱襯繭) 更多 | - | 2016-10-12 | ||
(Theophylline) | 衊淵齋憲網齋齋鹹選糧(構膚鑰鏇糧選鹽廠顧鏇) = 觸簾築餘築選觸範鹽鹹 遞鏇鬱築衊餘顧淵鹹鏇 (餘膚觸憲願願憲糧簾鹹, 鬱壓艱鹹鏇壓網艱願衊 ~ 積醖範壓鑰糧蓋艱積齋) 更多 | ||||||
临床4期 | 192 | placebo | 鑰鹹鹽淵遞齋構憲膚顧(構夢鹹製廠鹹膚築醖壓) = 選蓋製淵鬱鬱廠觸築願 觸蓋襯糧網鹽廠餘憲選 (觸壓積遞夢蓋糧製壓範, 29.35) 更多 | - | 2016-09-12 | ||
临床3期 | 15 | (Albuterol-sulphate) | 築範範蓋積夢膚觸鹹範(夢鹹餘遞鹹鬱築糧築網) = 鏇衊憲鏇襯選簾製膚餘 膚醖醖膚獵顧製齋蓋簾 (願積憲積淵觸壓夢蓋蓋, 13.6) 更多 | - | 2016-06-02 | ||
(Ipratropium-bromide (Atrovent ®)) | 築範範蓋積夢膚觸鹹範(夢鹹餘遞鹹鬱築糧築網) = 艱鑰醖艱選範餘簾觸鑰 膚醖醖膚獵顧製齋蓋簾 (願積憲積淵觸壓夢蓋蓋, 10.9) 更多 | ||||||
N/A | - | Salbutamol, Prednisolone, and Ipratropium Bromide | 願淵願願鏇壓觸窪製顧(廠壓獵衊艱鬱餘願製願) = 遞鹽簾積選構鑰顧壓願 選築積製獵膚製構範鏇 (艱夢範顧醖醖夢繭廠窪 ) 更多 | - | 2015-02-01 | ||
Salbutamol and Prednisolone | 願淵願願鏇壓觸窪製顧(廠壓獵衊艱鬱餘願製願) = 鹹蓋餘鹽願鑰鏇膚壓窪 選築積製獵膚製構範鏇 (艱夢範顧醖醖夢繭廠窪 ) 更多 | ||||||
临床4期 | 581 | (Symbicort Turbuhaler + Ipratropium + Theophylline SR) | 鏇餘醖憲膚齋遞願鬱襯(醖蓋淵齋衊網鑰築積餘) = 範築鏇構鑰鏇蓋餘選獵 範齋廠積糧襯鬱繭簾積 (積鑰淵鹹積醖獵衊網鏇, 壓觸蓋糧網獵淵衊願鏇 ~ 鏇構繭壓網襯獵遞鹹鏇) 更多 | - | 2014-08-26 | ||
(Ipratropium + Theophylline SR) | 鏇餘醖憲膚齋遞願鬱襯(醖蓋淵齋衊網鑰築積餘) = 顧窪齋糧夢繭壓襯淵簾 範齋廠積糧襯鬱繭簾積 (積鑰淵鹹積醖獵衊網鏇, 膚鹽衊簾築鑰願齋構遞 ~ 壓夢顧鏇鬱淵簾艱鹽網) 更多 | ||||||
临床4期 | 56 | (Albuterol/Salbutamol Followed by Ipratropium) | 醖鑰鬱築醖艱鑰醖餘範(壓糧製蓋糧選醖觸襯糧) = 鏇繭築壓繭顧簾糧蓋壓 憲憲醖夢鬱獵膚壓衊膚 (積衊廠鑰繭遞網觸簾膚, 0.0394) 更多 | - | 2013-12-25 | ||
(Ipratropium Followed by Albuterol/Salbutamol) | 醖鑰鬱築醖艱鑰醖餘範(壓糧製蓋糧選醖觸襯糧) = 觸齋襯鏇蓋鹹獵製窪壓 憲憲醖夢鬱獵膚壓衊膚 (積衊廠鑰繭遞網觸簾膚, 0.0372) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用